RBC Capital analyst Deane Dray maintained a Hold rating on Danaher Corp (NYSE:DHR). on Thursday, setting a price target of $254, which is approximately 7.29% above the present share price of $236.75.
Dray expects Danaher Corp. to post earnings per share (EPS) of $1.18 for the first quarter of 2021.
The current consensus among 9 TipRanks analysts is for a Strong Buy rating of shares in Danaher, with an average price target of $264.44.
The analysts price targets range from a high of $280 to a low of $250.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $5.88 billion and a net profit of $1.09 billion. The company's market cap is $168.18 billion.
According to TipRanks.com, RBC Capital analyst Deane Dray is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 9.2% and a 58.35% success rate.
Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment comprises of analytical instruments, reagents, consumables, software, and services that hospitals, physician's offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1969 and is headquartered in Washington, DC.